| Size | Price | |
|---|---|---|
| Other Sizes |
| Targets |
DMT-5Me-dC(Bz)-CE Phosphoramidite does not have a direct biological target as a drug. It is a chemical reagent used in the synthesis of oligonucleotides. The 5-methylcytidine base introduced by this phosphoramidite can enhance the stability and binding affinity of DNA duplexes. The compound is used in the preparation of locked nucleic acids (LNAs), which are modified oligonucleotides with improved spectral properties and target binding. Its value is in nucleic acid chemistry and the development of oligonucleotide-based therapeutics and diagnostics.
|
|---|---|
| ln Vitro |
DMT-5Me-dC(Bz)-CE Phosphoramidite does not have direct in vitro biological activity. It is a chemical reagent used in oligonucleotide synthesis. Its in vitro activity would be evaluated indirectly through the biological activity of the modified oligonucleotides synthesized using it. The compound itself is not tested in biological assays but is used as a reagent in chemical synthesis.
|
| ln Vivo |
DMT-5Me-dC(Bz)-CE Phosphoramidite does not have in vivo biological activity. It is a chemical reagent used in oligonucleotide synthesis. The compound is not intended for administration to animals or humans. Its biological relevance is indirect, through the modified oligonucleotides that are synthesized using it.
|
| Enzyme Assay |
In vitro enzyme/receptor binding assays are not applicable to DMT-5Me-dC(Bz)-CE Phosphoramidite as it is a chemical reagent used in oligonucleotide synthesis, not a drug targeting a specific enzyme or receptor. The compound is characterized by chemical analysis methods such as HPLC for purity assessment (typically ≥95%), NMR for structural confirmation, and mass spectrometry. No enzyme or receptor binding studies have been reported.
|
| Cell Assay |
Cell culture experiments are not applicable to DMT-5Me-dC(Bz)-CE Phosphoramidite as it is a chemical reagent used in oligonucleotide synthesis, not a pharmacologically active compound. The compound is used in chemical synthesis and is not intended for cell-based assays. Researchers using this compound should focus on its chemical properties and synthetic applications.
|
| Animal Protocol |
In vivo animal experiments are not applicable to DMT-5Me-dC(Bz)-CE Phosphoramidite as it is a chemical reagent, not a therapeutic agent. The compound is not intended for administration to animals. Its biological relevance is indirect, through the modified oligonucleotides that are synthesized using it.
|
| ADME/Pharmacokinetics |
Pharmacokinetic properties are not applicable to DMT-5Me-dC(Bz)-CE Phosphoramidite as it is a chemical reagent, not a therapeutic agent. The compound has a molecular formula of C47H54N5O8P and a molecular weight of 847.93. It is a solid. Storage: powder at -20°C for 3 years; in solvent at -80°C for 6 months. The compound is moisture-sensitive and should be stored under inert gas.
|
| Toxicity/Toxicokinetics |
Safety and toxicology data for DMT-5Me-dC(Bz)-CE Phosphoramidite are limited. As a chemical reagent, it should be handled with appropriate safety precautions. The compound is for research use only and is not for human therapeutic use. Standard laboratory safety practices should be followed. No specific toxicity data are available.
|
| References | |
| Additional Infomation |
DMT-5Me-dC(Bz)-CE Phosphoramidite has CAS number 105931-57-5, molecular formula C47H54N5O8P, and molecular weight 847.93. It is used to introduce 5-methylcytidine into DNA chains to enhance stability and binding affinity. It is used in the preparation of LNAs for optimizing fluorescent oligonucleotide probes. Purity: ≥95%. Not for human use; for research purposes only.
|
| Molecular Formula |
C47H54N5O8P
|
|---|---|
| Molecular Weight |
847.934133052826
|
| Exact Mass |
847.371
|
| CAS # |
105931-57-5
|
| PubChem CID |
15374208
|
| Appearance |
White to off-white solid powder
|
| LogP |
8.851
|
| Hydrogen Bond Donor Count |
1
|
| Hydrogen Bond Acceptor Count |
10
|
| Rotatable Bond Count |
19
|
| Heavy Atom Count |
61
|
| Complexity |
1490
|
| Defined Atom Stereocenter Count |
3
|
| SMILES |
CC1=CN(C(=O)N=C1NC(=O)C2=CC=CC=C2)[C@H]3C[C@@H]([C@H](O3)COC(C4=CC=CC=C4)(C5=CC=C(C=C5)OC)C6=CC=C(C=C6)OC)OP(N(C(C)C)C(C)C)OCCC#N
|
| InChi Key |
AGMUHEZFYUECLW-QUZMAVINSA-N
|
| InChi Code |
InChI=1S/C47H54N5O8P/c1-32(2)52(33(3)4)61(58-28-14-27-48)60-41-29-43(51-30-34(5)44(50-46(51)54)49-45(53)35-15-10-8-11-16-35)59-42(41)31-57-47(36-17-12-9-13-18-36,37-19-23-39(55-6)24-20-37)38-21-25-40(56-7)26-22-38/h8-13,15-26,30,32-33,41-43H,14,28-29,31H2,1-7H3,(H,49,50,53,54)/t41-,42+,43+,61?/m0/s1
|
| Chemical Name |
N-[1-[(2R,4S,5R)-5-[[bis(4-methoxyphenyl)-phenylmethoxy]methyl]-4-[2-cyanoethoxy-[di(propan-2-yl)amino]phosphanyl]oxyoxolan-2-yl]-5-methyl-2-oxopyrimidin-4-yl]benzamide
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
DMSO : ~250 mg/mL (~294.84 mM)
|
|---|---|
| Solubility (In Vivo) |
Note: Listed below are some common formulations that may be used to formulate products with low water solubility (e.g. < 1 mg/mL), you may test these formulations using a minute amount of products to avoid loss of samples.
Injection Formulations
Injection Formulation 1: DMSO : Tween 80： Saline = 10 : 5 : 85 (i.e. 100 μL DMSO stock solution → 50 μL Tween 80 → 850 μL Saline)(e.g. IP/IV/IM/SC) *Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH ₂ O to obtain a clear solution. Injection Formulation 2: DMSO : PEG300 ：Tween 80 : Saline = 10 : 40 : 5 : 45 (i.e. 100 μL DMSO → 400 μLPEG300 → 50 μL Tween 80 → 450 μL Saline) Injection Formulation 3: DMSO : Corn oil = 10 : 90 (i.e. 100 μL DMSO → 900 μL Corn oil) Example: Take the Injection Formulation 3 (DMSO : Corn oil = 10 : 90) as an example, if 1 mL of 2.5 mg/mL working solution is to be prepared, you can take 100 μL 25 mg/mL DMSO stock solution and add to 900 μL corn oil, mix well to obtain a clear or suspension solution (2.5 mg/mL, ready for use in animals). View More
Injection Formulation 4: DMSO : 20% SBE-β-CD in saline = 10 : 90 [i.e. 100 μL DMSO → 900 μL (20% SBE-β-CD in saline)] Oral Formulations
Oral Formulation 1: Suspend in 0.5% CMC Na (carboxymethylcellulose sodium) Oral Formulation 2: Suspend in 0.5% Carboxymethyl cellulose Example: Take the Oral Formulation 1 (Suspend in 0.5% CMC Na) as an example, if 100 mL of 2.5 mg/mL working solution is to be prepared, you can first prepare 0.5% CMC Na solution by measuring 0.5 g CMC Na and dissolve it in 100 mL ddH2O to obtain a clear solution; then add 250 mg of the product to 100 mL 0.5% CMC Na solution, to make the suspension solution (2.5 mg/mL, ready for use in animals). View More
Oral Formulation 3: Dissolved in PEG400 (Please use freshly prepared in vivo formulations for optimal results.) |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 1.1793 mL | 5.8967 mL | 11.7934 mL | |
| 5 mM | 0.2359 mL | 1.1793 mL | 2.3587 mL | |
| 10 mM | 0.1179 mL | 0.5897 mL | 1.1793 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
